Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01549314 · ClinicalTrials.gov registry record
Cystic Fibrosis Related Bone Disease: the Role of CFTR
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 79
- Enrollment target
NCT01549314: Completed study, sponsored by Massachusetts General Hospital.
NCT01549314 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 79 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01549314 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 79 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether ivacaftor, a recently FDA-approved CFTR potentiator, improves bone micro-architecture and strength in patients with cystic fibrosis with at least one G551D CFTR mutation.
Primary Outcome
Change in cortical volumetric bone mineral density at the radius
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2012-04 |
| Est. Completion | 2020-02 |
What the finished NCT01549314 record still lists
NCT01549314 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 79 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01549314 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01549314 about?
NCT01549314 is a clinical study titled "Cystic Fibrosis Related Bone Disease: the Role of CFTR". The purpose of this study is to determine whether ivacaftor, a recently FDA-approved CFTR potentiator, improves bone micro-architecture and strength in patients with cystic fibrosis with at least one G551D CFTR mutation.
What is the current status of trial NCT01549314?
This trial is currently completed. The enrollment target is 79 participants. The study started on 2012-04. Estimated completion is 2020-02.
Who is sponsoring clinical trial NCT01549314?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05798897 · 79 participants · Phase 1
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- NCT06042439 · 79 participants · NA
AM vs PM Exercise Training
- NCT06223555 · 79 participants · NA
Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia